Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Haematology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Haematology Other
    Community Practice Study Confirms Association Between ESAs, Venous Thromboembolism - (DGNews)
    X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - (N Engl J Med)
    Postoperative Anticoagulation Therapy Necessary in Patients Following Major Surgery: Presented at ASA - (DGDispatch)
    New USP Standards for Heparin Products Will Result in Decreased Potency - (DGNews)
    Thrombomodulin mutations in atypical hemolytic-uremic syndrome - (N Engl J Med)

    News archive

     Recent webcasts/CME - Haematology Other
    • Managing Treatment- and Disease-Related Complications in Multiple Myeloma
    • Thrombosis in Multiple Myeloma: Choice of Thromboprophylaxis Depends on Type of Therapy and Individual Risk of Patient
    • Evolving Strategies for Chronic Idiopathic Thrombocytepenic Purpura
      PreAnesthetic Assessment of the Patient on Low Dose Aspirin and a Thienopyridine - Part 2
      PreAnesthetic Assessment of the Patient on Low Dose Aspirin and a Thienopyridine - Part 1

      Webcasts/CME archive

       Recent cases - Haematology Other
        A Latent Form Of Essential Thrombocythemia Presenting As Portal Cavernoma
        Polycythemia Vera as a Presentation of Renal Angiomyolipoma: A Case Report
        Cobalamin Deficiency Resulting in a Rare Haematological Disorder: A Case Report
        Complications of Evans' Syndrome in an Infant with Hereditary Spherocytosis: A Case Report
        Multisystem Failure Due to Three Coexisting Autoimmune Diseases

        Cases archive
          




        my personal edition > haematology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Abnormal Levels of Coagulation Factors Mean Increased Risk for Venous Thrombosis in Postmenopausal Women Who Take Hormones: Presented at ASH

        By Sophie Bainbridge

        ATLANTA, GA -- December 10, 2007 -- Preliminary data from two trials of the Women's Health Initiative (WHI) show that abnormalities in coagulation factor levels can identify postmenopausal women who are at increased risk of venous thrombosis (VT) if they elect to begin hormone replacement therapy (HRT).

        Measurement of these factors may help women and their physicians make informed decisions about whether or not to take HRT, said Mary Cushman, MD, MSc, Professor of Medicine, University of Vermont, Burlington, Vermont, here at the 49th American Society of Hematology (ASH) Annual Meeting and Exposition.

        Factors associated with an elevated VT risk in the presence of HRT included free protein S, D-dimer, and plasmin antiplasmin complex (PAP).

        To determine if certain coagulation factors could identify women who would be at high risk of venous thrombosis if they take HRT, Dr. Cushman and colleagues conducted a nested case-control study that measured baseline levels of these factors in 215 women who developed VT and 867 age-matched controls. All of the women were participants in one of two placebo-controlled, double-blind, randomized WHI trials evaluating conjugated equine estrogens alone (E), or estrogen plus medroxyprogesterone acetate (E + P), or placebo.

        The mean age of the women in this analysis was 66, and ranged from 50 to 79 years.

        The investigators studied procoagulant, anticoagulant, and fibrinolysis markers in blood samples that were obtained at the time the women entered the WHI studies.

        They found that women who had low levels of protein C and free protein S, and the highest levels of D-dimer, PAP, and prothrombin fragment 1-2 had an elevated risk of VTE.

        The most important predictor of VTE risk was a high D-dimer level. For example, women with the highest levels of D-dimer who were on HRT had a 6-fold increase in their risk for VTE compared with women with the lowest levels of D-dimer who were randomized to placebo, Dr. Cushman said.

        However, she cautioned that assays for D-dimer are currently problematic, with a lack of standardization. Because of this, "routine testing for D-dimer is not yet ready for prime time," she said.

        "These results really are preliminary, and we need to do more studies to confirm our findings. But I think this is a first step in being able to tease out those women who will have an increased risk from hormonal therapy from those whose risk is comparatively small. Women want this information to help them make intelligent choices about whether or not to take HRT."


        [Presentation title: Coagulation Factors, Postmenopausal Hormone Replacement Therapy and the Risk of Venous Thrombosis: The WHI Clinical Trials of Postmenopausal Hormone Therapy. Abstract 127]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send